Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AARD Aardvark Therapeutics	$13.39 -3.4%	$10.93	$4.88 ▼ $19.58	$290.56M	N/A	76,430 shs	676,046 shs
PHAT Phathom Pharmaceuticals	$9.74 +2.0%	$5.75	$2.21 ▼ $19.71	$679.95M	0.08	1.53 million shs	1.23 million shs
RZLT Rezolute	$4.35 +0.9%	$3.98	$2.22 ▼ $6.19	$372.01M	1.04	627,136 shs	10.25 million shs
TRLPF Acerus Pharmaceuticals	$0.22	$0.22	$0.08 ▼ $0.34	$56.90M	2.6	5,474 shs	N/A

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AARD Aardvark Therapeutics	0.00%	+20.31%	+27.28%	+78.30%	+1,338,999,900.00%
PHAT Phathom Pharmaceuticals	0.00%	-6.53%	+129.72%	+55.34%	-5.44%
RZLT Rezolute	0.00%	+5.84%	+6.36%	+50.00%	+1.16%
TRLPF Acerus Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	3.8447 of 5 stars	4.5	1.0	0.0	0.0	2.6	5.0	0.6
RZLT Rezolute	3.1056 of 5 stars	3.6	1.0	0.0	0.0	4.2	4.2	0.0
TRLPF Acerus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AARD Aardvark Therapeutics	3.00	Buy	$31.25	133.38% Upside
PHAT Phathom Pharmaceuticals	3.00	Buy	$17.50	79.67% Upside
RZLT Rezolute	3.14	Buy	$11.83	172.03% Upside
TRLPF Acerus Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest TRLPF, AARD, RZLT, and PHAT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/9/2025	PHAT Phathom Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $17.00
6/9/2025	PHAT Phathom Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/6/2025	PHAT Phathom Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00
5/15/2025	AARD Aardvark Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$21.00 ➝ $20.00
5/14/2025	RZLT Rezolute	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$12.00
5/2/2025	PHAT Phathom Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$10.00 ➝ $5.00
5/2/2025	PHAT Phathom Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $12.00
5/2/2025	PHAT Phathom Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $20.00
4/28/2025	RZLT Rezolute	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/21/2025	PHAT Phathom Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
4/17/2025	PHAT Phathom Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$12.00 ➝ $10.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	$55.25M	12.31	N/A	N/A	($3.71) per share	-2.63
RZLT Rezolute	N/A	N/A	N/A	N/A	$2.19 per share	N/A
TRLPF Acerus Pharmaceuticals	$7.38M	7.71	N/A	N/A	N/A	∞

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AARD Aardvark Therapeutics	-$20.59M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	-$334.33M	-$5.24	N/A	N/A	N/A	-422.42%	N/A	-90.11%	8/6/2025 (Estimated)
RZLT Rezolute	-$68.46M	-$1.15	N/A	N/A	N/A	N/A	-70.09%	-63.08%	9/18/2025 (Estimated)
TRLPF Acerus Pharmaceuticals	-$18.79M	-$0.08	N/A	∞	N/A	-254.66%	-346.72%	-94.54%	N/A

Latest TRLPF, AARD, RZLT, and PHAT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/14/2025	N/A	AARD Aardvark Therapeutics	-$0.70	-$0.71	-$0.01	-$0.71	N/A	N/A
5/13/2025	Q3 2025	RZLT Rezolute	-$0.22	-$0.27	-$0.05	-$0.27	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RZLT Rezolute	N/A	N/A	N/A	N/A	N/A
TRLPF Acerus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AARD Aardvark Therapeutics	N/A	25.86	25.86
PHAT Phathom Pharmaceuticals	N/A	3.58	3.54
RZLT Rezolute	N/A	8.43	8.43
TRLPF Acerus Pharmaceuticals	0.64	1.35	0.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AARD Aardvark Therapeutics	N/A
PHAT Phathom Pharmaceuticals	99.01%
RZLT Rezolute	82.97%
TRLPF Acerus Pharmaceuticals	0.02%

Insider Ownership

Company	Insider Ownership
AARD Aardvark Therapeutics	N/A
PHAT Phathom Pharmaceuticals	24.10%
RZLT Rezolute	18.39%
TRLPF Acerus Pharmaceuticals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AARD Aardvark Therapeutics	18	21.70 million	N/A	N/A
PHAT Phathom Pharmaceuticals	110	69.81 million	52.99 million	Optionable
RZLT Rezolute	40	85.52 million	69.79 million	Optionable
TRLPF Acerus Pharmaceuticals	29	258.62 million	N/A	Not Optionable

TRLPF, AARD, RZLT, and PHAT Headlines

Recent News About These Companies

Takeda Pharmaceutical Co. Ltd. ADR

February 8, 2024 | wsj.com

Other OTC Pharmaceuticals - Lithuania

September 17, 2023 | statista.comS

2023 A Big Year For Testosterone: AbbVie And ANI Pharmaceuticals Best Positioned To Benefit

January 1, 2023 | seekingalpha.com

Acerus Reports Second Quarter 2022 Financial Results

August 9, 2022 | financialpost.comF

Acerus Reports Fourth Quarter and Full Year 2021 Financial Results

March 15, 2022 | financialpost.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRLPF, AARD, RZLT, and PHAT Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

$13.39 -0.47 (-3.39%)

As of 06/27/2025 04:00 PM Eastern

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Phathom Pharmaceuticals NASDAQ:PHAT

$9.74 +0.19 (+1.99%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$9.66 -0.08 (-0.82%)

As of 05:14 AM Eastern

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Rezolute NASDAQ:RZLT

$4.35 +0.04 (+0.93%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$4.54 +0.19 (+4.34%)

As of 04:58 AM Eastern

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Acerus Pharmaceuticals OTCMKTS:TRLPF

$0.22 0.00 (0.00%)

As of 07/21/2023

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time